Handling of Ventricular Fibrillation in the Emergency Setting

Frontiers in Pharmacology
Zoltán SzabóPéter P Nánási

Abstract

Ventricular fibrillation (VF) and sudden cardiac death (SCD) are predominantly caused by channelopathies and cardiomyopathies in youngsters and coronary heart disease in the elderly. Temporary factors, e.g., electrolyte imbalance, drug interactions, and substance abuses may play an additive role in arrhythmogenesis. Ectopic automaticity, triggered activity, and reentry mechanisms are known as important electrophysiological substrates for VF determining the antiarrhythmic therapies at the same time. Emergency need for electrical cardioversion is supported by the fact that every minute without defibrillation decreases survival rates by approximately 7%-10%. Thus, early defibrillation is an essential part of antiarrhythmic emergency management. Drug therapy has its relevance rather in the prevention of sudden cardiac death, where early recognition and treatment of the underlying disease has significant importance. Cardioprotective and antiarrhythmic effects of beta blockers in patients predisposed to sudden cardiac death were highlighted in numerous studies, hence nowadays these drugs are considered to be the cornerstones of the prevention and treatment of life-threatening ventricular arrhythmias. Nevertheless, other medical thera...Continue Reading

References

Jan 1, 1978·The American Journal of Cardiology·J D FisherS Furman
Feb 19, 1987·The New England Journal of Medicine·J W Mason
Jun 1, 1985·Journal of the American College of Cardiology·A Garson, D G McNamara
Nov 1, 1994·Journal of Cardiovascular Pharmacology·S P LubicJ C Giacomini
Mar 1, 1995·The Annals of Pharmacotherapy·J E TisdaleB J Zarowitz
Nov 1, 1993·European Heart Journal·C Funck-Brentano
Feb 1, 1994·Journal of Cardiovascular Electrophysiology·M S Spach, M E Josephson
Nov 1, 1993·Annals of Emergency Medicine·M P LarsenA P Hallstrom
Dec 15, 1993·Annals of Internal Medicine·R J MyerburgA Castellanos
May 30, 1998·Pacing and Clinical Electrophysiology : PACE·D M Roden
Jun 6, 1998·Cardiovascular Research·M Näbauer, S Kääb
Apr 20, 1999·Circulation·X JouvenP Ducimetière
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Nov 25, 2000·Journal of the American College of Cardiology·M Malik, V N Batchvarov
Feb 22, 2001·Journal of Molecular and Cellular Cardiology·E CerbaiA Mugelli
Jul 20, 2001·International Journal of Cardiology·C CardosoA G Siqueira-Filho
Feb 22, 2002·The New England Journal of Medicine·UNKNOWN Hypothermia after Cardiac Arrest Study Group
Mar 22, 2002·The New England Journal of Medicine·Arthur J MossUNKNOWN Multicenter Automatic Defibrillator Implantation Trial II Investigators
Jul 12, 2002·Drugs·Peter M Haddad, Ian M Anderson
Jan 22, 2003·Acta Psychiatrica Scandinavica·D M Taylor
Sep 3, 2003·Journal of Cardiovascular Electrophysiology·Cesar Alberte, Douglas P Zipes
Nov 5, 2003·Heart·Yee Guan Yap, A John Camm
Apr 20, 2004·Cardiovascular Research·Stephan Rohr
Sep 4, 2004·Psychosomatics·W Victor R Vieweg, Mark A Wood
Sep 29, 2004·Resuscitation·Thomas D ReaRoger D White
Oct 20, 2004·Circulation·James B YoungUNKNOWN Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees

❮ Previous
Next ❯

Citations

Jul 12, 2020·Journal of Cardiac Surgery·Ahmed F ElmahroukAhmed A Jamjoom
Oct 17, 2020·Minerva cardioangiologica·Elena Е KharkovskayaIrina V Mukhina
Mar 2, 2021·Frontiers in Pharmacology·Zoltán SzabóLóránt Székvölgyi

❮ Previous
Next ❯

Methods Mentioned

BETA
Assist

Software Mentioned

RESOLVD
LUCAS
AutoPulse

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.